Skystar Bio Pharmaceutical Company announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2013. For the quarter, the company reported revenue of $15,992,408 against $8,933,005 a year ago. Income from operations was $10,354,234 against $8,397,894 a year ago. Net income was $3,734,197 against $2,731,254 a year ago. Basic and diluted earnings per share were $0.49 against $0.36 a year ago. Income before provision for income taxes was $4,516,174 against $3,448,417 a year ago.

For the nine months, the company reported revenue of $32,858,294 against $25,730,190 a year ago. Income from operations was $4,737,701 against $3,641,389 a year ago. Income before provision for income taxes was $9,997,829 against $8,103,779 a year ago. Net income was $8,197,811 against $6,334,874 a year ago. Basic and diluted earnings per share were $1.08 against $0.85 a year ago. Net cash used in operating activities was $10,020,354 against $6,439,293 a year ago. Purchases of property, plant and equipment were $9,290 against $157,782 a year ago.

The company reiterated its fiscal 2013 guidance to be in the range of $40 million to $45 million. The company expects solid revenue growth and expansion in fiscal 2014.